|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
TRANSPLANTATION
From the Departments of Hematology, and
Immunohematology and Blood Transfusion, Leiden University
Medical Center, The Netherlands.
Graft rejection or graft-versus-host (GVH) disease after
HLA-identical stem cell transplantation is the result of recognition of
minor histocompatibility antigens (mHags) by immunocompetent T
lymphocytes from recipient or donor origin, respectively. Cytolytic T
lymphocyte (CTL) clones can be isolated during graft rejection and GVH
disease to identify mHags and their corresponding genes. Thus far, all
human mHags identified appeared to be HLA class I-restricted. Here, we
report the characterization of the first human HLA class II-restricted
sex-linked mHag involved in GVH disease. Previously, we isolated an
HLA-DQ5-restricted CD4+ CTL clone from a male patient with
chronic myeloid leukemia who developed acute GVH disease grade III-IV
after transplantation of HLA genotypically identical female stem cells.
Using a panel of female HLA-DQ5+ EBV cells that we stably
transfected with Y chromosome-specific genes, we determined that the
HLA class II male-specific mHag (H-Y) was encoded by the Y
chromosome-specific gene DBY. The H-Y epitope was
localized in the DBY protein using female HLA-DQ5+
peripheral blood mononuclear cells loaded with DBY protein fragments. The minimal peptide sequence leading to maximal recognition by the
specific HLA-DQ5-restricted CTL clone was characterized as the
12-amino acid sequence HIENFSDIDMGE. Although the epitope differed by
3 amino acids from its X-homolog DBX, only 2 polymorphisms were shown
to be essential for recognition by the CTL clone.
(Blood. 2002;99:3027-3032) HLA-identical stem cell transplantation can
be complicated by graft-versus-host (GVH) disease or graft rejection.
Both complications are initiated by T lymphocytes that recognize minor
histocompatibility antigens (mHags) presented by HLA
molecules.1-3 These mHags are peptides derived from
polymorphic proteins that differ between donor and
recipient.4 T-lymphocyte clones recognizing mHags can be
isolated from patients who developed GVH disease or graft rejection.2,5-7 A number of mHags have been identified.
The HLA-A2-restricted mHag HA-1 was found to be a nonapeptide derived from the KIAA0223 gene, and HA-2 originated from a gene that
was a member of the nonfilament-forming class I myosin
family.8,9 Both mHags were exclusively expressed on
hematopoietic cells. The immunogenicity of mHag HA-8 resulted from
differential antigen processing due to a polymorphic residue at the
N-terminus of the antigen.10 HB-1 was an
HLA-B44-restricted mHag specific for B-cell acute lymphoblastic
leukemia.11 These identified mHags were derived from
polymorphic proteins that contained one amino acid difference compared
with their homologous allelic counterparts.
Male-specific mHags were shown to be involved in HLA-identical
sex-mismatched stem cell transplantation.12,13
SMCY was the first gene identified encoding human HLA-B7-
and HLA-A2-restricted H-Y mHags.14,15 A systematic search
of the nonrecombining region of the human Y chromosome identified other
ubiquitously expressed genes that were potential candidates to encode
H-Y antigens.16 Recently, the DFFRY and
UTY genes were identified as genes coding for human major
histocompatibility complex (MHC) class I-restricted H-Y antigens,
demonstrating that human H-Y antigens are encoded by multiple
Y-specific genes.17-20 Amino acid differences between the
male-specific mHags and their X-homologs varied from 1 to 4 amino acids.
All human mHags identified to date are MHC class I-restricted and are
recognized by cytolytic T lymphocytes (CTLs). However, efficient in
vivo priming of these CTLs during graft rejection or GVH disease
generally requires the participation of CD4+ T-helper
lymphocytes, which recognize epitopes in MHC class II molecules.21,22 This help for CTLs may either be mediated
by cytokine production by T-helper lymphocytes or by activation of the
antigen-presenting cell via CD40-CD40L interaction.23
Furthermore, the involvement of CD4+ T lymphocytes in graft
rejection or GVH disease is not solely restricted to provide help to
CTLs. In MHC class I-deficient mice, CD4+ CTLs induced and
maintained GVH disease after allogeneic mHag-mismatched stem cell
transplantation.24 Moreover, transgenic female mice that
expressed the T-cell receptor (TCR) from a MHC class II-restricted H-Y-specific T-cell clone rapidly rejected male skin grafts in a
CD4-dependent fashion.25 Recently, it was demonstrated
that this T-cell clone recognized an epitope derived from the murine DBY protein.26
In this study, we report the identification of the first human MHC
class II-restricted male-specific mHag. The mHag was recognized by a
CD4+ CTL clone that was isolated from a male patient who
developed acute GVH disease grade III-IV after transplantation of HLA
genotypically identical female stem cells.27 The H-Y
antigen presented by the HLA-DQ5 molecule was encoded by the
DBY gene. The minimal peptide sequence for maximal
recognition was characterized as the 12-residue peptide HIENFSDIDMGE.
CTLs and cell lines
Cloning of Y-specific genes
Retroviral transduction of female HLA-DQ5+ EBV cells The Y-specific cDNAs were cloned into a retroviral vector. The Moloney murine leukemia virus-based retroviral vector LZRS and packaging cells -NX-A used for this purpose were kindly
provided by G. Nolan.28 A bicistronic retroviral vector
was constructed in which the multiple cloning site is linked to the
downstream internal ribosome entry sequence and the marker gene green
fluorescent protein (GFP).29 After cloning of the
Y-specific cDNAs in this vector, the constructs were transfected into
-NX-A cells using calcium phosphate (Life Technologies,
Gaithersburg, MD). After 2 days at 37°C, 2 µg/mL puromycin
(Clontech Laboratories, Palo Alto, CA) was added to the cells. Ten to
14 days after transfection, 6 × 106 cells were plated
per 10-cm Petri dish (Becton Dickinson, San Jose, CA) in 10 mL IMDM
supplemented with 10% fetal calf serum without puromycin. The next day
the medium was refreshed, and on the following day retroviral
supernatant was harvested, centrifuged, and frozen in aliquots at
 70°C. The Y-specific cDNAs were transduced into female
HLA-DQ5+ EBV cells using the method developed by Hanenberg
et al.30 Briefly, 5 × 106 EBV cells were
cultured on recombinant human fibronectin fragments CH-296
(RetroNectin, Takara, Otzu, Japan) coated Petri dishes together
with 1 mL thawed retroviral supernatant for 18 hours at 37°C, washed,
and transferred to 24-well culture plates. After 3 to 5 days, the
transduction efficiency, measured by the expression of the GFP marker,
was analyzed by flow cytometry. Then, Y gene-transduced female EBV
cells were FACS-sorted based on their GFP positivity.
Recognition assay of Y gene-transduced EBV cells 51Cr-release assays were used to determine lysis of target cells by the HLA-DQ5 HY CTL. Male, female, or Y gene-transduced female EBV target cells were labeled with 100 µCi (3.7 MBq) Na51CrO4. After 1 hour at 37°C, the cells were washed 3 times with RPMI supplemented with 2% fetal calf serum. Na51CrO4-labeled EBV cells were plated in a 96-well V-bottom microtiter plate in 100 µL IMDM plus 10% human serum at 2000 cells per well. In cold target inhibition assays, 20 000 Y gene-transduced EBV cells were added to the Na51CrO4-labeled male EBV. Then, 20 000 HLA-DQ5 HY CTLs were added in 100 µL IMDM plus 10% human serum. 51Cr release was measured after incubation at 37°C for 4 hours.DBY protein synthesis and CTL recognition assay DBY proteins were synthesized using the pCRT7 TOPO TA cloning kit according to the manufacturer's procedure (Invitrogen, Carlsbad, CA). The DBY PCR product was ligated into the pCRT7/NT-TOPO vector. DBY fragments were obtained by amplification of the cloned DBY construct with specific primers annealing at internal DBY sequences. The overlapping DBY PCR products were also ligated into the pCRT7/NT-TOPO vector. The cloning reactions were transformed into chemically competent TOP10F' Escherichia coli cells, which were spread on Luria-Bertani (LB) plates containing 100 µg/mL ampicillin. Then, colonies were selected and analyzed for insert and correct orientation. DBY-pCRT7/NT-TOPO constructs were transformed into chemically competent BL21(DE3)pLysS cells, which were spread on LB plates containing 100 µg/mL ampicillin and 34 µg/mL chloramphenicol. Three colonies of each construct were separately added to 10 mL complete LB medium containing 100 µg/mL ampicillin and 34 µg/mL chloramphenicol and grown for 6 hours at 37°C. After overnight incubation at 4°C, the cultures of each construct were collected and added to 750 mL complete LB medium. After incubation for 2 hours at 37°C, expression of the DBY proteins was induced by adding isopropyl -D-thiogalactoside to the culture medium at a final concentration of 0.5 mM. After incubation for 4 hours at 37°C, cultures were centrifuged for 10 minutes at 3000g. Then,
inclusion bodies were isolated from the cell pellets using B-PER
bacterial protein extraction reagent according to the manufacturer's
procedure (Pierce, Rockford, IL). The isolated inclusion bodies that
contained the DBY proteins were dissolved in a buffer containing 20 mM
Tris-HCl, 100 mM NaCl, 50 mM imidazole, and 8 M ureum. Correct
expression of the DBY constructs was evaluated by loading samples on
sodium dodecyl sulfate-polyacrylamide gel electrophoresis and staining with Coomassie blue (Bio-Rad Laboratories, Hercules, CA).
Irradiated (20 Gy) HLA-DQ5+ PBMCs were plated at 50 000
cells per well in a 96-well flat-bottom microtiter plate in 100 µL IMDM plus 10% human serum. DBY proteins were added to the cells at a
final concentration of 10 µg/mL. After incubation of 24 hours at
37°C, 10 000 HLA-DQ5 HY CTLs were added in 100 µL IMDM plus 10%
human serum supplemented with 120 U/mL interleukin-2. After 16 hours at
37°C, supernatant was harvested and the amount of interferon Peptide synthesis and peptide recognition assays Peptides were synthesized by solid-phase strategies on an automated multiple peptide synthesizer (SyroII, MultiSynTech, Witten, Germany) and characterized by mass spectrometry. The purity of the peptides was determined by analytical reversed-phase high-performance liquid chromatography and proved to be at least 80%. Irradiated (50 Gy) HLA-DQ5+ female EBV cells were plated at 50 000 cells per well in a 96-well flat-bottom microtiter plate in 200 µL acidified RPMI 1640, pH 5.0, containing various concentrations of peptides. After 2 hours of incubation at 37°C, the cells were washed 3 times with RPMI 1640. Then, 25 000 HLA-DQ5 HY CTLs were added in 200 µL IMDM plus 10% human serum supplemented with 120 U/mL interleukin-2. After 16 hours at 37°C, supernatant was harvested and IFN- content was measured.
DBY real-time quantitative reverse transcriptase-PCR analysis PCR was performed using the ABI PRISM 7700 Sequence Detection System (PE Applied Biosystems, Foster City, CA). Double dye fluorogenic probes (Eurogentec, Seraing, Belgium) were designed using Primer Express software (PE Applied Biosystems). The DBY probe was labeled at the 3' end with the quencher dye TAMRA (6-carboxy-tetramethylrhodamine) and at the 5' end with the reporter dye TET (4,7,2',7'-tetrachloro-6-carboxyfluorescein). The forward DBY primer was located in exon 2 (5'-AAC TGG ACC AGC AGC TTG CTA AT-3') and the reverse primer in exon 3 (5'-TTC ACT GAA ATA ACC AGG CTT TCC T-3'), generating a PCR product of 150 base pairs. The double dye probe was chosen between the forward and reverse primers (DBY 5'-(FAM)-CCT GAA CTG TCT TTA TCA TGG AAT CCT TTA GAT GCT-(TAMRA)-3').For amplification, the qPCR core kit was used according to the manufacturer's procedure (Eurogentec). PCR amplifications were performed in duplicate experiments in 96-well 0.2-mL reaction plates (Thermofast 96 AB0600, ABgene, Epsom, United Kingdom), sealed with Clear Strong Seal (ABgene), and run on an ABI PRISM 7700 (PE Applied Biosystems). The PCR was started after activating the Hot GoldStar polymerase for 10 minutes at 95°C, followed by 55 cycles consisting of 15 seconds at 95°C, 30 seconds at 60°C, and elongation for 30 seconds at 60°C. A real-time fluorescence plot was obtained based upon normalized fluorescence signals. The threshold cycle was determined, ie, the fractional cycle number at which the amount of amplified target reached a fixed threshold. This threshold was defined as 10 times the SD of the baseline fluorescent signal, ie, the normalized fluorescence signal of PCR cycles 3 to 15. As a negative control, milliQ water was used. DBY messenger RNA expression was analyzed in human multiple tissue culture (MTC) panel I containing first-strand cDNA generated from the human tissues of heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas and human MTC panel II containing cDNA from spleen, thymus, prostate, testis, ovary, small intestine, colon, and peripheral blood leukocytes (Clontech Laboratories). Skin tissue was derived from a male individual, total RNA was isolated with Trizol (Gibco) according to the manufacturer's procedure, and cDNA was prepared from RNA using Moloney murine leukemia virus BRL reverse transcriptase (Gibco) for 60 minutes at 37°C.
Transduction of female HLA-DQ5+ EBV cells with Y genes Female HLA-DQ5+ EBV cells were transduced with the DBY, EIF-1AY, RPS4Y, and TB4Y genes using the retroviral vector LZRS that contained the marker gene GFP. Transduction efficiency as measured by fluorescence-activated cell sorter (FACS) analysis was 20% (data not shown). Y gene-transduced female EBV cells were FACS sorted based on their GFP positivity, resulting in a 99% GFP+ cell population (data not shown).Identification of the gene encoding the HLA-DQ5-restricted H-Y T-cell epitope To determine whether one of the Y genes coded for the HLA-DQ5-restricted H-Y T-cell epitope, the Y gene-transduced EBV cells were tested for recognition by the specific CTL clone in a 51Cr-release assay. As shown in Figure 1A, HLA-DQ5+ female EBV cells transduced with the DBY gene (EBV/DBY) were recognized by the HLA-DQ5 HY CTL clone. The lysis was comparable to HLA-DQ5+ male EBV cells. To analyze whether the epitope recognized on EBV/DBY was identical to the H-Y epitope presented by male EBV cells, we measured the CTL-induced lysis of 51Cr-labeled male EBV cells after addition of a 10-fold excess of unlabeled female EBV/DBY cells. As demonstrated in Figure 1B, lysis of male EBV cells could be blocked by EBV/DBY, whereas unlabeled EBV cells transduced with the control vector containing the GFP did not affect the CTL-induced lysis of male EBV cells. This illustrated that the TCR from the CTLs binds to HLA/epitope complexes expressed on both female EBV/DBY cells as well as male EBV cells.
Localization of the HLA-DQ-restricted H-Y epitope in the DBY gene Because no HLA-DQ5-binding motifs were available, the DBY protein could not be screened for HLA-DQ5-binding peptides. Therefore, DBY protein fragments were used to localize the H-Y epitope in the DBY protein. To analyze whether the DBY-derived H-Y epitope could be exogenously processed by antigen presenting cells, the DBY protein was synthesized and added to HLA-DQ5+ female PBMCs. As shown in Figure 2, the HLA-DQ5 HY CTL clone released high amounts of IFN- when stimulated with PBMCs loaded with
the DBY protein. Overlapping DBY protein fragments were synthesized and
added to PBMCs. Two overlapping DBY protein fragments were recognized
by the HLA-DQ5 HY CTL, illustrating that the H-Y epitope was situated
on the DBY protein between amino acid 164 and 209 (Figure 2). This
region contained only 4 amino acids that differed from the DBX-homolog
protein. Peptides spanning this region were synthesized. Two peptides
containing the common amino acids PHIENFSDIDMGE were recognized by the
HLA-DQ5 HY CTL (Figure 3).
Identification of minimal epitope recognized by HLA-DQ5 HY CTL The peptide PHIENFSDIDMGE was loaded on female HLA-DQ5+ EBV cells and tested for recognition by the HLA-DQ5 HY CTL. As shown in Figure 4, PHIENFSDIDMGE induced IFN- production by the HLA-DQ5 HY CTL in a
dose-dependent manner. N- and C-terminal-trimmed variants of this
peptide were used to characterize the minimal H-Y epitope (Figure 4).
Recognition considerably decreased after removal of the histidine
residue on position 2, and further removal of N-terminal amino acids
resulted in a further reduction of IFN- release by HLA-DQ5 HY CTL.
Trimming of the C-terminal glutamic acid residue led to a slightly
diminished recognition, while removal of the glycine residue completely
abolished IFN- release by HLA-DQ5 HY CTL. These results indicated
that the minimal peptide leading to recognition by the HLA-DQ5 HY CTL
clone was the 10-amino acid sequence IENFSDIDMG, while the minimal
peptide for maximal recognition was the 12-residue peptide
HIENFSDIDMGE.
Two polymorphisms in H-Y epitope are essential for T-cell recognition The H-Y epitope HIENFSDIDMGE differed by 3 amino acids from its X-homolog HIESFSDVEMGE. To determine whether all 3 polymorphisms were equally important for recognition by the HLA-DQ5 HY CTL, 3 peptides each containing 1 DBX-homolog amino acid at positions P4, P8, or P9 were tested. As shown in Figure 5, IFN- release by HLA-DQ5 HY CTL was completely abrogated when the
amino acid at P4 or P9 was substituted by the X-homolog residue. In
contrast, substitution of the isoleucin residue at P8 by the
DBX-derived valine resulted in an even enhanced cytokine release by the
specific CTL clone. The X-homolog peptide HIESFSDVEMGE and DBY-derived peptides containing 2 X-homolog amino acids were not recognized by
HLA-DQ5 HY CTL (data not shown).
Ubiquitous expression of the DBY gene To determine whether DBY was expressed in multiple tissues, we performed real-time quantitative reverse transcriptase-PCR analysis on human MTC panels containing first-strand cDNA derived from multiple tissues. The expression level of DBY was similar in all tissues tested with the exception of ovary tissue (data not shown).
T-lymphocyte clones isolated from patients who developed graft rejection or GVH disease after HLA-identical stem cell transplantation can be used to identify mHags and their corresponding genes. This led to the isolation of a number of MHC class I-restricted human mHags.8-11 These mHags were derived from polymorphic genes, which encoded proteins that contained one amino acid difference compared with the proteins derived from their homologous allelic counterparts. CTL clones recognizing male-specific mHags were mainly isolated during graft rejection. Male-specific mHags or H-Y epitopes were shown to be encoded by the ubiquitously expressed Y-chromosome-specific genes SMCY, DFFRY, and UTY.14,15,17-20 The epitopes presented in different MHC class I molecules contained 1 to 4 amino acid differences compared with their X-homologs. Previously, we isolated an H-Y-specific MHC class II-restricted CD4+ CTL clone during severe GVH disease.27 In this paper, we report the identification of DBY as the gene encoding the HLA-DQ5-restricted H-Y epitope. DBY belongs to a well-conserved family of genes coding for RNA helicases. This family of proteins shares a group of conserved motifs, including the sequence Asp-Glu-Ala-Asp or the so-called DEAD motif. These proteins are involved in diverse cellular functions, including splicing, ribosomal assembly, and translation. The DBY-derived H-Y epitope leading to maximal recognition by the
HLA-DQ5 HY CTL clone was characterized as the 12-amino acid sequence
HIENFSDIDMGE. The epitope contained 3 different amino acids There are no HLA-DQ5-binding motifs known, and it is therefore
difficult to point out the anchor residues in this epitope. However, a
peptide binding motif for HLA-DQ6 has been characterized by determining
the influence of amino acid sustitutions on HLA-DQ6 binding of a
peptide derived from insulin B.31 The The identification of DBY as a gene encoding a MHC class II-restricted H-Y epitope demonstrates that multiple male antigens complexed with MHC class I or class II molecules derived from different Y-specific genes are involved in GVH disease and graft rejection. We demonstrated that DBY was expressed at similar levels in all tissues tested, including GVH disease target organs. Because DBY is ubiquitously expressed, it may be the expression of the HLA-DQ5 molecule that determines whether or not tissues become GVH disease target organs. These cells may process the DBY protein and may present the DBY-derived epitope in HLA-DQ5, resulting in activation of male-specific T lymphocytes. The role of different H-Y antigens in GVH disease needs to be further evaluated. HLA class I-restricted H-Y-specific T cells present in male patients during GVH disease may be monitored by using HLA/HY peptide tetrameric complexes. Tetrameric complexes of HLA-A2 or HLA-B7 with SMCY-derived H-Y epitopes were used to monitor H-Y-specific T cells during GVH disease of male patients transplanted with female stem cells.33 A significant increase of H-Y-specific CTLs during acute and chronic GVH disease could be visualized. The involvement of MHC class II-restricted H-Y-specific CD4+ T lymphocytes during GVH disease may also be monitored if tetrameric complexes with sufficient binding affinity to the TCR can be generated.34 Immunodominancy of the HLA-DQ5-associated DBY-derived H-Y epitope may be evaluated by determining the presence of T lymphocytes specific for this epitope during GVH disease in other male HLA-DQ5+ patients who received female stem cells. In conclusion, we report the identification of the first human HLA class II-restricted male-specific mHag. The mHag was recognized by a CD4+ CTL clone that was isolated from a male patient who developed acute GVH disease grade III-IV after transplantation of HLA genotypically identical female stem cells.27 The H-Y mHag presented by the HLA-DQ5 molecule was encoded by the DBY gene. The minimal peptide sequence leading to maximal recognition by the specific HLA-DQ5-restricted CTL clone was characterized as the 12-amino acid sequence HIENFSDIDMGE.
Submitted April 30, 2001; accepted December 5, 2001.
Supported by the Dutch Cancer Society (grant RUL 99-2028) and the JA Cohen Institute for Radiopathology and Radiation Protection.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Mario H. J. Vogt, Leiden University Medical Center, Dept of Hematology, C2-R, PO Box 9600, 2300 RC Leiden, The Netherlands; e-mail: m.h.j.vogt{at}lumc.nl.
1. Voogt PJ, Fibbe WE, Marijt WA, et al. Rejection of bone-marrow graft by recipient-derived cytotoxic T lymphocytes against minor histocompatibility antigens. Lancet. 1990;335:131-134[CrossRef][Medline] [Order article via Infotrieve]. 2. Marijt WA, Kernan NA, Diaz-Barrientos T, et al. Multiple minor histocompatibility antigen-specific cytotoxic T lymphocyte clones can be generated during graft rejection after HLA-identical bone marrow transplantation. Bone Marrow Transplant. 1995;16:125-132[Medline] [Order article via Infotrieve]. 3. Goulmy E. Minor histocompatibility antigens in man and their role in transplantation. In: Morris PJ,Tilney NC, eds. Transplantation Reviews. Philadelphia, PA: WB Saunders; 1988:29-54. 4. Goulmy E. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev. 1997;157:125-140[CrossRef][Medline] [Order article via Infotrieve].
5.
Faber LM, Luxemburg-Heijs SA, Rijnbeek M, Willemze R, Falkenburg JH.
Minor histocompatibility antigen-specific, leukemia-reactive cytotoxic T cell clones can be generated in vitro without in vivo priming using chronic myeloid leukemia cells as stimulators in the presence of
6.
Warren EH, Greenberg PD, Riddell SR.
Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution.
Blood.
1998;91:2197-2207 7. van Els CA, D'Amaro J, Pool J, et al. Immunogenetics of human minor histocompatibility antigens: their polymorphism and immunodominance. Immunogenetics. 1992;35:161-165[Medline] [Order article via Infotrieve].
8.
den Haan JM, Meadows LM, Wang W, et al.
The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism.
Science.
1998;279:1054-1057
9.
den Haan JM, Sherman NE, Blokland E, et al.
Identification of a graft versus host disease-associated human minor histocompatibility antigen.
Science.
1995;268:1476-1480
10.
Brickner AG, Warren EH, Caldwell JA, et al.
The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing.
J Exp Med.
2001;193:195-206
11.
Dolstra H, Fredrix H, Maas F, et al.
A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia.
J Exp Med.
1999;189:301-308 12. Goulmy E, Blokland E, van Rood J, Charmot D, Malissen B, Mawas C. Production, expansion, and clonal analysis of T cells with specific HLA- restricted male lysis. J Exp Med. 1980;152:182s-190s. 13. Goulmy E, Termijtelen A, Bradley BA, van Rood JJ. Y-antigen killing by T cells of women is restricted by HLA. Nature. 1977;266:544-545[CrossRef][Medline] [Order article via Infotrieve].
14.
Wang W, Meadows LR, den Haan JM, et al.
Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein.
Science.
1995;269:1588-1590 15. Meadows L, Wang W, den Haan JM, et al. The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity. 1997;6:273-281[CrossRef][Medline] [Order article via Infotrieve].
16.
Lahn BT, Page DC.
Functional coherence of the human Y chromosome.
Science.
1997;278:675-680
17.
Vogt MHJ, de Paus RA, Voogt PJ, Willemze R, Falkenburg JHF.
DFFRY codes for a new human male-specific minor transplantation antigen involved in bone marrow graft rejection.
Blood.
2000;95:1100-1105
18.
Pierce RA, Field ED, den Haan JM, et al.
Cutting edge: the HLA-A*0101-restricted HY minor histocompatibility antigen originates from DFFRY and contains a cysteinylated cysteine residue as identified by a novel mass spectrometric technique.
J Immunol.
1999;163:6360-6364
19.
Warren EH, Gavin MA, Simpson E, et al.
The human UTY gene encodes a novel HLA-B8-restricted H-Y antigen.
J Immunol.
2000;164:2807-2814
20.
Vogt MH, Goulmy E, Kloosterboer FM, et al.
UTY gene codes for an HLA-B60-restricted human male-specific minor histocompatibility antigen involved in stem cell graft rejection: characterization of the critical polymorphic amino acid residues for T-cell recognition.
Blood.
2000;96:3126-3132 21. van Els CA, Bakker A, Zwinderman AH, Zwaan FE, van Rood JJ, Goulmy E. Effector mechanisms in graft-versus-host disease in response to minor histocompatibility antigens, II: evidence of a possible involvement of proliferative T cells. Transplantation. 1990;50:67-71[Medline] [Order article via Infotrieve]. 22. van Els C, Bakker A, Zwaan F, van Rood JJ, Goulmy E. Incidence of anti-host cytotoxic and proliferative T cell responses after HLA-identical bone marrow transplantation (BMT). Transplant Proc. 1989;21:2987-2988[Medline] [Order article via Infotrieve]. 23. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998;393:480-483[CrossRef][Medline] [Order article via Infotrieve]. 24. Shenoy S, Desch K, Duffy B, Thorson P, Mohanakumar T. Analysis of graft-versus-host disease (GVHD) and graft rejection using MHC class I-deficient mice. Clin Exp Immunol. 1998;112:188-195[CrossRef][Medline] [Order article via Infotrieve].
25.
Zelenika D, Adams E, Mellor A, et al.
Rejection of H-Y disparate skin grafts by monospecific CD4+ Th1 and Th2 cells: no requirement for CD8+ T cells or B cells.
J Immunol.
1998;161:1868-1874 26. Scott D, Addey C, Ellis P, et al. Dendritic cells permit identification of genes encoding MHC class II- restricted epitopes of transplantation antigens. Immunity. 2000;12:711-720[CrossRef][Medline] [Order article via Infotrieve].
27.
Faber LM, Luxemburg-Heijs SA, Veenhof WF, Willemze R, Falkenburg JH.
Generation of CD4+ cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity.
Blood.
1995;86:2821-2828 28. Kinsella TM, Nolan GP. Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum Gene Ther. 1996;7:1405-1413[Medline] [Order article via Infotrieve].
29.
Heemskerk MH, Blom B, Nolan G, et al.
Inhibition of T cell and promotion of natural killer cell development by the dominant negative helix loop helix factor Id3.
J Exp Med.
1997;186:1597-1602 30. Hanenberg H, Xiao XL, Dilloo D, Hashino K, Kato I, Williams DA. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat Med. 1996;2:876-882[CrossRef][Medline] [Order article via Infotrieve].
31.
Ettinger RA, Kwok WW.
A peptide binding motif for HLA-DQA1*0102/DQB1*0602, the class II MHC molecule associated with dominant protection in insulin-dependent diabetes mellitus.
J Immunol.
1998;160:2365-2373 32. Carson RT, Vignali KM, Woodland DL, Vignali DA. T cell receptor recognition of MHC class II-bound peptide flanking residues enhances immunogenicity and results in altered TCR V region usage. Immunity. 1997;7:387-399[CrossRef][Medline] [Order article via Infotrieve]. 33. Mutis T, Gillespie G, Schrama E, Falkenburg JHF, Moss P, Goulmy E. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nat Med. 1999;5:839-842[CrossRef][Medline] [Order article via Infotrieve].
34.
Kwok WW, Liu AW, Novak EJ, et al.
HLA-DQ tetramers identify epitope-specific T cells in peripheral blood of herpes simplex virus type 2-infected individuals: direct detection of immunodominant antigen-responsive cells.
J Immunol.
2000;164:4244-4249
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  A. N. Stumpf, E. D. van der Meijden, C. A. M. van Bergen, R. Willemze, J. H. F. Falkenburg, and M. Griffioen Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity Blood, October 22, 2009; 114(17): 3684 - 3692. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. V. Rosinski, N. Fujii, J. K. Mito, K. K. W. Koo, S. M. Xuereb, O. Sala-Torra, J. S. Gibbs, J. P. Radich, Y. Akatsuka, B. J. Van den Eynde, et al. DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cells Blood, May 1, 2008; 111(9): 4817 - 4826. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Griffioen, E. D. van der Meijden, E. H. Slager, M. W. Honders, C. E. Rutten, S. A. P. van Luxemburg-Heijs, P. A. von dem Borne, J. J. van Rood, R. Willemze, and J. H. F. Falkenburg Identification of phosphatidylinositol 4-kinase type II {beta} as HLA class II-restricted target in graft versus leukemia reactivity PNAS, March 11, 2008; 105(10): 3837 - 3842. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. M. Heemskerk, R. S. Hagedoorn, M. A. W. G. van der Hoorn, L. T. van der Veken, M. Hoogeboom, M. G. D. Kester, R. Willemze, and J. H. F. Falkenburg Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex Blood, January 1, 2007; 109(1): 235 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Copelan Hematopoietic stem-cell transplantation. N. Engl. J. Med., April 27, 2006; 354(17): 1813 - 1826. [Full Text] [PDF]
|
|
|
|
 |
|
 L. T. van der Veken, R. S. Hagedoorn, M. M. van Loenen, R. Willemze, J.H. F. Falkenburg, and M. H.M. Heemskerk {alpha}{beta} T-Cell Receptor Engineered {gamma}{delta} T Cells Mediate Effective Antileukemic Reactivity. Cancer Res., March 15, 2006; 66(6): 3331 - 3337. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. M. Kloosterboer, S. A. P. van Luxemburg-Heijs, R. A. van Soest, H. M. E. van Egmond, R. Willemze, and J. H. F. Falkenburg Up-regulated expression in nonhematopoietic tissues of the BCL2A1-derived minor histocompatibility antigens in response to inflammatory cytokines: relevance for allogeneic immunotherapy of leukemia Blood, December 1, 2005; 106(12): 3955 - 3957. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Miklos, H. T. Kim, K. H. Miller, L. Guo, E. Zorn, S. J. Lee, E. P. Hochberg, C. J. Wu, E. P. Alyea, C. Cutler, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission Blood, April 1, 2005; 105(7): 2973 - 2978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ivanov, T. Aarts, S. Hol, A. Doornenbal, A. Hagenbeek, E. Petersen, and S. Ebeling Identification of a 40S Ribosomal Protein S4-Derived H-Y Epitope Able to Elicit a Lymphoblast-Specific Cytotoxic T Lymphocyte Response Clin. Cancer Res., March 1, 2005; 11(5): 1694 - 1703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Torikai, Y. Akatsuka, M. Miyazaki, E. H. Warren III, T. Oba, K. Tsujimura, K. Motoyoshi, Y. Morishima, Y. Kodera, K. Kuzushima, et al. A Novel HLA-A*3303-Restricted Minor Histocompatibility Antigen Encoded by an Unconventional Open Reading Frame of Human TMSB4Y Gene J. Immunol., December 1, 2004; 173(11): 7046 - 7054. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-G. Chai, E. James, H. Dewchand, E. Simpson, and D. Scott Transplantation tolerance induced by intranasal administration of HY peptides Blood, May 15, 2004; 103(10): 3951 - 3959. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Zorn, D. B. Miklos, B. H. Floyd, A. Mattes-Ritz, L. Guo, R. J. Soiffer, J. H. Antin, and J. Ritz Minor Histocompatibility Antigen DBY Elicits a Coordinated B and T Cell Response after Allogeneic Stem Cell Transplantation J. Exp. Med., April 19, 2004; 199(8): 1133 - 1142. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. B. Randolph, T. A. Gooley, E. H. Warren, F. R. Appelbaum, and S. R. Riddell Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants Blood, January 1, 2004; 103(1): 347 - 352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Miklos, H. T. Kim, E. Zorn, E. P. Hochberg, L. Guo, A. Mattes-Ritz, S. Viatte, R. J. Soiffer, J. H. Antin, and J. Ritz Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors Blood, January 1, 2004; 103(1): 353 - 359. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Weber, C. Lange, W. Gunther, M. Franz, E. Kremmer, and H.-J. Kolb Minor Histocompatibility Antigens on Canine Hemopoietic Progenitor Cells J. Immunol., June 15, 2003; 170(12): 5861 - 5868. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Akatsuka, T. Nishida, E. Kondo, M. Miyazaki, H. Taji, H. Iida, K. Tsujimura, M. Yazaki, T. Naoe, Y. Morishima, et al. Identification of a Polymorphic Gene, BCL2A1, Encoding Two Novel Hematopoietic Lineage-specific Minor Histocompatibility Antigens J. Exp. Med., June 2, 2003; 197(11): 1489 - 1500. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Murata, E. H. Warren, and S. R. Riddell A Human Minor Histocompatibility Antigen Resulting from Differential Expression due to a Gene Deletion J. Exp. Med., May 19, 2003; 197(10): 1279 - 1289. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Orsini, R. Bellucci, E. P. Alyea, R. Schlossman, C. Canning, S. McLaughlin, P. Ghia, K. C. Anderson, and J. Ritz Expansion of Tumor-specific CD8+ T Cell Clones in Patients with Relapsed Myeloma after Donor Lymphocyte Infusion Cancer Res., May 15, 2003; 63(10): 2561 - 2568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Sahara and N. Shastri Second Class Minors: Molecular Identification of the Autosomal H46 Histocompatibility Locus as a Peptide Presented by Major Histocompatibility Complex Class II Molecules J. Exp. Med., February 3, 2003; 197(3): 375 - 385. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
at
positions P4, P8, and P9
chain of HLA-DQ6
is identical to HLA-DQ5, and only the